ArticleOncotarget2018
Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- Protease-Activated Receptor-2 Promotes Metastasis: An Emerging Therapeutic Target.Molecular cancer research : MCR · 2026Review
- Article
- G protein-coupled receptors as novel therapeutic targets in non-small-cell lung cancer.Medical review (2021) · 2025Review
- PAR2 regulates proliferation, migration of lung cancer and chemotherapy sensitivity by involving PTEN pathway.Future science OA · 2025Article
- Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology.International journal of molecular sciences · 2025Review
- Epinephrine augments the phosphorylation of EGFR and promote the DNA synthesis and migration of cervical cancer cells.3 Biotech · 2025Article
- Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.Scientific reports · 2024Article
- Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress.Cancer discovery · 2024Article
- PAR2 promotes malignancy in lung adenocarcinoma.American journal of translational research · 2024Article
- TF/PAR2 Signaling Axis Supports the Protumor Effect of Neutrophil Extracellular Traps (NETs) on Human Breast Cancer Cells.Cancers · 2023Article
- EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells.Medical oncology (Northwood, London, England) · 2023Article
- Quercetin-loaded Liposomes Effectively Induced Apoptosis and Decreased the Epidermal Growth Factor Receptor Expression in Colorectal Cancer Cells: AnIranian journal of medical sciences · 2023Article
- Candidate Genes and Pathways in Cervical Cancer: A Systematic Review and Integrated Bioinformatic Analysis.Cancers · 2023Review
- Protease-activated receptors in health and disease.Physiological reviews · 2023Review
- Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer.Journal of biomedical science · 2022Article
- Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.International journal of molecular sciences · 2021Article
- Predictive value of protease-activated receptor-2 (PARJournal of cellular and molecular medicine · 2021Article
- Inhibition of PKC/MEK pathway suppresses β1-integrin and mitigates breast cancer cells proliferation.Toxicology reports · 2021Article
- Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- E6‑regulated overproduction of prostaglandin E2 may inhibit migration of dendritic cells in human papillomavirus 16‑positive cervical lesions.International journal of oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin-based chemoradiation is the standard treatment for cervical cancer, but chemosensitizing strategies are needed to improve patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.